Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis

Journal of Allergy and Clinical Immunology

Volumn 130, Issue 4, 2012, Pages

  Novak, Natalija ^a   Bieber, Thomas ^a   Hoffmann, Matthias ^b   FColster Holst, Regina ^c   Homey, Bernhard ^d   Werfel, Thomas ^e   Sager, Angelika ^f   Zuberbier, Torsten ^g  

^a UNIVERSITY OF BONN   (Germany)

^b Dermatology Practice   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d University Hospital DCusseldorf   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f LETI Pharma   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

AlLergy; Atopic Dermatitis; House Dust Mites; Specific Immunotherapy

Indexed keywords

DESLORATADINE; FUSIDIC ACID; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; LANOLIN ALCOHOL; LEVOCABASTINE; METHYLPREDNISOLONE; MOMETASONE FUROATE; PIMECROLIMUS; PLACEBO; PREDNICARBATE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHMA; ATOPIC DERMATITIS; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; IMMUNOTHERAPY; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SUBCUTANEOUS ALLERGEN SPECIFIC IMMUNOTHERAPY; TREATMENT DURATION;

EID: 84869141265     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2012.08.004     Document Type: Article

References (26)

1. Novak N, Simon D. Atopic dermatitis - from new pathophysiologic insights to individualized therapy. Allergy 2011;66:830-9.
2. Sheikh A, Hurwitz B, Shehata Y. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev 2007;(1):CD001563.
3. Darsow U, Vieluf D, Ring J. The atopy patch test: An increased rate of reactivity in patients who have an air-exposed pattern of atopic eczema. Br J Dermatol 1996; 135:182-6.
4. Tupker RA, De Monchy JG, Coenraads PJ. House-dust mite hypersensitivity, eczema, and other nonpulmonary manifestations of allergy. Allergy 1998; 53(48 Suppl):92-6.
5. Tupker RA, De Monchy JG, Coenraads PJ, Homan A, van der Meer JB. Induction of atopic dermatitis by inhalation of house dust mite. J Allergy Clin Immunol 1996; 97:1064-70.
6. Sager N, Feldmann A, Schilling G, Kreitsch P, Neumann C. House dust mitespecific T cells in the skin of subjects with atopic dermatitis: Frequency and lymphokine profile in the allergen patch test. J Allergy Clin Immunol 1992;89: 801-10.
7. Pajno GB, Peroni DG, Barberio G, Pietrobelli A, Boner AL. Predictive features for persistence of atopic dermatitis in children. Pediatr Allergy Immunol 2003;14: 292-5.
8. Patrizi A, Pileri A, Bellini F, Raone B, Neri I, Ricci G. Atopic dermatitis and the atopic march: What is new? J Allergy (Cairo) 2011;2011:279425.
9. Moniaga CS, Egawa G, Kawasaki H, Hara-Chikuma M, Honda T, Tanizaki H, et al. Flaky tail mouse denotes human atopic dermatitis in the steady state and by topical application with Dermatophagoides pteronyssinus extract. Am J Pathol 2010;176:2385-93.
10. Henderson J, Northstone K, Lee SP, Liao H, Zhao Y, Pembrey M, et al. The burden of disease associated with filaggrin mutations: A population-based, longitudinal birth cohort study. J Allergy Clin Immunol 2008;121:872-7.
11. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007;(1):CD001936.
12. Durham SR, Leung DY. One hundred years of allergen immunotherapy: Time to ring the changes. J Allergy Clin Immunol 2011;127:3-7.
13. Werfel T, Breuer K, Rueff F, Przybilla B, Worm M, Grewe M, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: A multi-centre, randomized, dose-response study. Allergy 2006;61:202-5.
14. Novak N. Allergen specific immunotherapy for atopic dermatitis. Curr Opin Allergy Clin Immunol 2007;7:542-6.
15. Bussmann C, Bockenhoff A, Henke H, Werfel T, Novak N. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol 2006;118:1292-8.
16. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980;92:44-7.
17. Bussmann C, Maintz L, Hart J, Allam JP, Vrtala S, Chen KW, et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: A pilot study. Clin Exp Allergy 2007;37:1277-85.
18. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. Int J Surg 2011;9:672-7.
19. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy 2006; 61(Suppl 82):1-20.
20. Platts-Mills TA, Hayden ML, Chapman MD, Wilkins SR. Seasonal variation in dust mite and grass-pollen allergens in dust from the houses of patients with asthma. J Allergy Clin Immunol 1987;79:781-91.
21. Kosik-Bogacka DI, Kalisinska E, Henszel L, Kuzna-Grygiel W. Seasonal dynamics of house dust mites in dust samples collected from sleeping places in north-western Poland. Zoonoses Public Health 2012;59:8-15.
22. Bieber T. Atopic dermatitis. N Engl J Med 2008;358:1483-94.
23. Gutowska-Owsiak D, Schaupp AL, Salimi M, Taylor S, Ogg GS. Interleukin-22 downregulates filaggrin expression and affects expression of profilaggrin processing enzymes. Br J Dermatol 2011;165:492-8.
24. Svensson A, Chambers C, Ganemo A, Mitchell SA. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Curr Med Res Opin 2011;27:1395-406.
25. Novak N, Thaci D, Hoffmann M, Folster-Holst R, Biedermann T, Homey B, et al. Subcutaneous immunotherapy with a depigmented polymerized birch pollen extract - a new therapeutic option for patients with atopic dermatitis. Int Arch Allergy Immunol 2011;155:252-6.
26. Kim ME, Kim JE, Sung JM, Lee JW, Choi GS, Nahm DH. Safety of accelerated schedules of subcutaneous allergen immunotherapy with house dust mite extract in patients with atopic dermatitis. J Korean Med Sci 2011;26:1159-64.